RXi Pharmaceuticals Corporation (NASDAQ:RXII)’s share price was down 0% during trading on Thursday . The stock traded as low as $0.50 and last traded at $0.51. Approximately 506,333 shares traded hands during trading, an increase of 3% from the average daily volume of 490,733 shares. The stock had previously closed at $0.51.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter in the prior year, the firm posted ($0.34) EPS. analysts forecast that RXi Pharmaceuticals Corporation will post -0.74 earnings per share for the current fiscal year.

In other RXi Pharmaceuticals Corporation news, insider Alexey Eliseev sold 176,800 shares of RXi Pharmaceuticals Corporation stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total transaction of $95,472.00. Following the transaction, the insider now owns 1,100,931 shares of the company’s stock, valued at approximately $594,502.74. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.71% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/rxi-pharmaceuticals-corporation-rxii-shares-down-0/1696431.html.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.